US Patent Issued to Sema4 OpCo on May 26 for "Polymorphic markers for pharmacogenetic HLA risk alleles" (New York Inventors)

ALEXANDRIA, Va., May 26 -- United States Patent no. 12,640,228, issued on May 26, was assigned to Sema4 OpCo Inc. (Stamford, Conn.).

"Polymorphic markers for pharmacogenetic HLA risk alleles" was invented by Paola Nicoletti (Rye, N.Y.) and Stuart A. Scott (NY, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "We have identified panels of proxy single nucleotide polymorphisms (SNPs) that are highly predictive of particular HLA risk alleles, and concordant across multi-ethnic populations. Accordingly, methods are provided involving clinical DNA testing for HLA panel markers to assess risk for life-threatening adverse drug reactions associated with the human leucocyte antigen (HLA) alleles HLA-B*57:01, HLA-B*...